TREATMENT OF COAGULATION DISEASE BY ADMINISTRATION OF RECOMBINANT vWF Russian patent published in 2017 - IPC A61K38/36 A61K38/37 A61P7/04 

FIELD: medicine.

SUBSTANCE: group of inventions relates to a method of treating von Willebrand's disease or hemophilia A in a patient in need of treatment comprising administering to the patient a recombinant vWF (vWF) factor so that the half-life of factor VIII is prolonged compared to a patient administered vWF derived from blood plasma, where pFB is not modified with an aqueous soluble polymer. In this case, the pFB is a composition of high molecular weight PV multimers containing at least 20% of the PV emperors or higher-order multimers, with the rVB having a higher specific activity than the vWF derived from the blood plasma. The group of inventions also relates to a method for treating hemophilia A or vWF in a patient in need of treatment that includes administering to the patient a recombinant vWF (vWF) factor, wherein the half-life of FVIII is at least 1.5 times higher than the half-life of FVIII in the patient being treated Von Willebrand factor derived from blood plasma.

EFFECT: increase in the half-life of FVIII in the treatment of von Willebrand disease or haemophilia A in the subject.

29 cl, 5 ex, 22 dwg, 34 tbl